The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Interactions between Siglec-7/9 receptors and ligands influence NK cell–dependent tumor immunosurveillance
Open accessAbstract
Alteration of the surface glycosylation pattern on malignant cells potentially affects tumor immunity by directly influencing interactions with glycan-binding proteins (lectins) on the surface of immunomodulatory cells. The sialic acid-binding Ig-like lectins Siglec-7 and -9 are MHC class I-independent inhibitory receptors on human NK cells that recognize sialic acid-containing carbohydrates. Here, we found that the presence of Siglec-9 defined a subset of cytotoxic NK cells with a mature phenotype and enhanced chemotactic potential. Interestingly, this Siglec-9+ NK cell population was reduced in the peripheral blood of cancer patients. Broad analysis of primary tumor samples revealed that ligands of Siglec-7 and -9 were expressed on human cancer cells of different histological types. Expression of Siglec-7 and -9 ligands was associated with susceptibility of NK cell-sensitive tumor cells and, unexpectedly, of presumably NK cell-resistant tumor cells to NK cell-mediated cytotoxicity. Together, these observations have direct implications for NK cell-based therapies and highlight the requirement to consider both MHC class I haplotype and tumor-specific glycosylation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset
Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., Carson, W. E., & Caligiuri, M. A. (2001) · Blood · doi:10.1182/blood.v97.10.3146 · Cited by 1,449
The sweet and sour of cancer: glycans as novel therapeutic targets
Fuster, M. M., & Esko, J. D. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1649 · Cited by 1,383
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,283
Immune infiltration in human tumors: a prognostic factor that should not be ignored
Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., & Fridman, W.-H. (2010) · Oncogene · doi:10.1038/onc.2009.416 · Cited by 1,087
Telomere end-replication problem and cell aging
Levy, M. Z., Allsopp, R. C., Futcher, A. B., Greider, C. W., & Harley, C. B. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90096-3 · Cited by 1,069
Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism.
Hakomori, S. (1996) · PubMed · Cited by 987
Glycan-based interactions involving vertebrate sialic-acid-recognizing proteins
Varki, A. (2007) · Nature · doi:10.1038/nature05816 · Cited by 853
Protein-glycan interactions in the control of innate and adaptive immune responses
van Kooyk, Y., & Rabinovich, G. A. (2008) · Nature Immunology · doi:10.1038/ni.f.203 · Cited by 807
Lopez-Vergès, S., Milush, J. M., Pandey, S., York, V. A., Arakawa-Hoyt, J., Pircher, H., Norris, P. J., Nixon, D. F., & Lanier, L. L. (2010) · Blood · doi:10.1182/blood-2010-04-282301 · Cited by 752
Ljunggren, H. G., & Kärre, K. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.6.1745 · Cited by 736
Björkström, N. K., Riese, P., Heuts, F., Andersson, S., Fauriat, C., Ivarsson, M. A., Björklund, A. T., Flodström-Tullberg, M., Michaëlsson, J., Rottenberg, M. E., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281675 · Cited by 734
Comparative studies of human FcRIII-positive and negative natural killer cells.
Nagler, A., Lanier, L. L., Cwirla, S., & Phillips, J. H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.10.3183 · Cited by 696
NK cells and cancer immunosurveillance
Waldhauer, I., & Steinle, A. (2008) · Oncogene · doi:10.1038/onc.2008.267 · Cited by 682
Carbohydrate‐mediated cell adhesion in cancer metastasis and angiogenesis
Kannagi, R., Izawa, M., Koike, T., Miyazaki, K., & Kimura, N. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03219.x · Cited by 572
Siglecs—the major subfamily of I-type lectins
Varki, A., & Angata, T. (2006) · Glycobiology · doi:10.1093/glycob/cwj008 · Cited by 518
Diversity in cell surface sialic acid presentations: implications for biology and disease
Varki, N. M., & Varki, A. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700656 · Cited by 515
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells
Jacobs, R., Hintzen, G., Kemper, A., Beul, K., Kempf, S., Behrens, G., Sykora, K.-W., & Schmidt, R. E. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4 · Cited by 475
Flow cytometry and FISH to measure the average length of telomeres (flow FISH)
Baerlocher, G. M., Vulto, I., de Jong, G., & Lansdorp, P. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.263 · Cited by 449
Self-citationRomagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
Curti, A., Ruggeri, L., D'Addio, A., Bontadini, A., Dan, E., Motta, M. R., Trabanelli, S., Giudice, V., Urbani, E., Martinelli, G., et al. (2011) · Blood · doi:10.1182/blood-2011-01-329508 · Cited by 406
Immunoreceptor tyrosine‐based inhibition motifs: a quest in the past and future
Daëron, M., Jaeger, S., Du Pasquier, L., & Vivier, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00666.x · Cited by 370
Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H. F., Ritter, E., Ku, G. Y., Jungbluth, A. A., Segal, N. H., Rasalan, T. S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810114105 · Cited by 348
Zamai, L., Ponti, C., Mirandola, P., Gobbi, G., Papa, S., Galeotti, L., Cocco, L., & Vitale, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4011 · Cited by 292
Nicoll, G., Ni, J., Liu, D., Klenerman, P., Munday, J., Dubock, S., Mattei, M.-G., & Crocker, P. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.48.34089 · Cited by 253
Nicoll, G., Avril, T., Lock, K., Furukawa, K., Bovin, N., & Crocker, P. R. (2003) · European Journal of Immunology · doi:10.1002/eji.200323693 · Cited by 245
Tumour-associated carbohydrate antigens in breast cancer
Cazet, A., Julien, S., Bobowski, M., Burchell, J., & Delannoy, P. (2010) · Breast Cancer Research · doi:10.1186/bcr2577 · Cited by 241
The Sialome—Far More Than the Sum of Its Parts
Cohen, M., & Varki, A. (2010) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2009.0148 · Cited by 232
Falco, M., Biassoni, R., Bottino, C., Vitale, M., Sivori, S., Augugliaro, R., Moretta, L., & Moretta, A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.6.793 · Cited by 222
von Gunten, S., Yousefi, S., Seitz, M., Jakob, S. M., Schaffner, T., Seger, R., Takala, J., Villiger, P. M., & Simon, H.-U. (2005) · Blood · doi:10.1182/blood-2004-10-4112 · Cited by 217
Self-citationYamaji, T., Teranishi, T., Alphey, M. S., Crocker, P. R., & Hashimoto, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110146200 · Cited by 209
Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28−/− mice
Maier, S., Tertilt, C., Chambron, N., Gerauer, K., Hüser, N., Heidecke, C.-D., & Pfeffer, K. (2001) · Nature Medicine · doi:10.1038/87880 · Cited by 207
Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes
Belisle, J. A., Horibata, S., Jennifer, G. A., Petrie, S., Kapur, A., André, S., Gabius, H.-J., Rancourt, C., Connor, J., Paulson, J. C., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-118 · Cited by 207
Evidence for NK Cell Subsets Based on Chemokine Receptor Expression
Berahovich, R. D., Lai, N. L., Wei, Z., Lanier, L. L., & Schall, T. J. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.11.7833 · Cited by 191
Siglecs as targets for therapy in immune-cell-mediated disease
O’Reilly, M. K., & Paulson, J. C. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.02.005 · Cited by 187
Basic and Clinical Immunology of Siglecs
Von Gunten, S., & Bochner, B. S. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1443.011 · Cited by 167
Self-citationEBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
White, R. E., Rämer, P. C., Naresh, K. N., Meixlsperger, S., Pinaud, L., Rooney, C., Savoldo, B., Coutinho, R., Bödör, C., Gribben, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58092 · Cited by 166
Self-citationAugmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo
Koh, C. Y., Blazar, B. R., George, T., Welniak, L. A., Capitini, C. M., Raziuddin, A., Murphy, W. J., & Bennett, M. (2001) · Blood · doi:10.1182/blood.v97.10.3132 · Cited by 160
von Gunten, S., Schaub, A., Vogel, M. T., Stadler, B. M., Miescher, S., & Simon, H. (2006) · Blood · doi:10.1182/blood-2006-05-021568 · Cited by 139
Self-citationStrowig, T., Chijioke, O., Carrega, P., Arrey, F., Meixlsperger, S., Rämer, P. C., Ferlazzo, G., & Münz, C. (2010) · Blood · doi:10.1182/blood-2010-02-270678 · Cited by 116
Self-citationTargeting Siglecs—A novel pharmacological strategy for immuno- and glycotherapy
Jandus, C., Simon, H., & von Gunten, S. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.05.018 · Cited by 103
Self-citationKannagi, R., Sakuma, K., Miyazaki, K., Lim, K., Yusa, A., Yin, J., & Izawa, M. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01455.x · Cited by 100
Miyazaki, K., Sakuma, K., Kawamura, Y. I., Izawa, M., Ohmori, K., Mitsuki, M., Yamaji, T., Hashimoto, Y., Suzuki, A., Saitō, Y., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1100605 · Cited by 95
Ohta, M., Ishida, A., Toda, M., Akita, K., Inoue, M., Yamashita, K., Watanabe, M., Murata, T., Usui, T., & Nakada, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.079 · Cited by 94
Kawasaki, Y., Ito, A., Withers, D. A., Taima, T., Kakoi, N., Saito, S., & Arai, Y. (2010) · Glycobiology · doi:10.1093/glycob/cwq116 · Cited by 93
Cohen, M., Elkabets, M., Perlmutter, M., Porgador, A., Voronov, E., Apte, R. N., & Lichtenstein, R. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001635 · Cited by 75
Cell Death Modulation by Intravenous Immunoglobulin
von Gunten, S., & Simon, H. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9411-8 · Cited by 38
Self-citation
Cited by
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Siglec-mediated regulation of immune cell function in disease
Macauley, M. S., Crocker, P. R., & Paulson, J. C. (2014) · Nature Reviews Immunology · doi:10.1038/nri3737 · Cited by 1,122
Harnessing innate immunity in cancer therapy
Demaria, O., Cornen, S., Daëron, M., Morel, Y., Medzhitov, R., & Vivier, E. (2019) · Nature · doi:10.1038/s41586-019-1593-5 · Cited by 957
Metadata
- Authors
- Jandus, C., Boligan, K. F., Chijioke, O., Liu, H., Dahlhaus, M., Démoulins, T., Schneider, C., Wehrli, M., Hunger, R. E., Baerlocher, G. M., Simon, H.-U., Romero, P., Münz, C., & von Gunten, S.
- Venue
- Journal of Clinical Investigation
- Published
- 2014-02-24
- Volume
- 124
- Issue
- 4
- Pages
- 1810-1820
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2088717724
- Cited by
- 439
- References
- 52
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.